Literature DB >> 26116478

Hemiarch and Total Arch Surgery in Patients With Previous Repair of Acute Type I Aortic Dissection.

Ourania Preventza1, Matt D Price2, Katherine H Simpson2, Denton A Cooley3, Elizabeth Pocock4, Kim I de la Cruz4, Susan Y Green2, Scott A LeMaire4, Todd K Rosengart2, Joseph S Coselli4.   

Abstract

BACKGROUND: We examined our contemporary experience with hemiarch and total arch replacement in patients with previous acute type I aortic dissection.
METHODS: Over an 8.5-year period, 137 consecutive patients (median age 58 years, interquartile range, 50 to 67) underwent hemiarch or total transverse aortic arch replacement a median of 7.7 years (range, 67 days to 32 years; interquartile range, 2.8 to 12.3 years) after previous acute type I aortic dissection repair. Interventions involving only the aortic root, aortic valve, descending aorta, or thoracoabdominal aorta were excluded. Multivariate analysis of 20 potential preoperative and intraoperative risk factors was performed to examine early death, neurologic deficit, composite endpoint (operative death, permanent neurologic deficit, or hemodialysis at discharge), and long-term mortality.
RESULTS: Total arch replacement was performed in 103 patients (75.2%), hemiarch replacement in 34 (24.8%), and elephant trunk procedures in 77 (56.2%). Thirty-one repairs (22.6%) were emergent or urgent. There were 16 operative deaths (11.7%), 4 permanent strokes (3.6%), and 21 (15.3%) instances of the composite endpoint. In the multivariate analysis, congestive heart failure and cardiopulmonary bypass time independently predicted operative mortality (p = 0.0027, p = 0.018). Emergency operation approached significance for stroke (p = 0.088). Predictors of long-term mortality (during a median follow-up period of 5.1 years, 95% confidence interval: 4.4 to 5.8) were female sex (p = 0.0036), congestive heart failure (p = 0.0045), and circulatory arrest time (p = 0.0013); preoperative pulmonary disease approached significance (p = 0.074). Five-year survival was 73.2%.
CONCLUSIONS: In patients with previous acute type I aortic dissection repair, hemiarch and total arch operations have respectable morbidity and survival rates. Congestive heart failure predicts operative death, long-term mortality, and our adverse event endpoint. Cardiopulmonary bypass time predicts operative mortality, and female sex and circulatory arrest time predict long-term mortality.
Copyright © 2015 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26116478     DOI: 10.1016/j.athoracsur.2015.03.095

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Surgical management and outcomes of type A dissection-the Mayo Clinic experience.

Authors:  Alduz Cabasa; Alberto Pochettino
Journal:  Ann Cardiothorac Surg       Date:  2016-07

2.  Predictors of patent false lumen of the aortic arch after hemiarch replacement.

Authors:  Gaku Uchino; Takeki Ohashi; Hiroshi Iida; Masao Tadakoshi; Souichirou Kageyama; Masato Furui; Noriko Kodani
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-08-02

3.  Regional Practice Patterns and Outcomes of Surgery for Acute Type A Aortic Dissection.

Authors:  Robert B Hawkins; J Hunter Mehaffey; Emily A Downs; Lily E Johnston; Leora T Yarboro; Clifford E Fonner; Alan M Speir; Jeffrey B Rich; Mohammed A Quader; Gorav Ailawadi; Ravi K Ghanta
Journal:  Ann Thorac Surg       Date:  2017-06-06       Impact factor: 4.330

4.  Outcome of the frozen elephant trunk procedure as a redo operation.

Authors:  Till Joscha Demal; Lennart Bax; Jens Brickwedel; Tilo Kölbel; Eik Vettorazzi; Franziska Sitzmann; Hermann Reichenspurner; Christian Detter
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-06-28

5.  Successful Embolization Therapy through Reentry Tear in the Right Subclavian Artery for Treating Patent False Lumen in the Aortic Arch Formed after Type A Dissection Repair.

Authors:  Hirohito Ishii; Kunihide Nakamura; Eisaku Nakamura; Koji Furukawa; Kouichiro Ochiai
Journal:  Ann Vasc Dis       Date:  2017-09-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.